Last reviewed · How we verify
Neurotox (GADOLINIUM)
At a glance
| Generic name | GADOLINIUM |
|---|---|
| Sponsor | BioActive Nutritional, Inc. |
| Drug class | Acetylcholine Release Inhibitor [EPC] |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- numbness
- tingling
- muscle cramps
- nerve pain
Common side effects
Key clinical trials
- A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis (PHASE2)
- Imaging Techniques in MRI
- Imperial Prostate 9 - ATLAS (Approaches To Long-Term Active Surveillance) (NA)
- Evaluation of Gadolinium Based Contrast Agents for Portable MR Imaging Systems (NA)
- Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy (PHASE1)
- In Vivo Measurement of the Accuracy of the "Neurolocate" Module of the Neurosurgical Robot "Neuromate" in Its Application to Deep Brain Stimulation
- Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance (PHASE2)
- Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neurotox CI brief — competitive landscape report
- Neurotox updates RSS · CI watch RSS
- BioActive Nutritional, Inc. portfolio CI